Antares Pharma Inc (ATRS.OQ)
ATRS.OQ on NASDAQ Stock Exchange Capital Market
2.34USD
26 Apr 2018
2.34USD
26 Apr 2018
Change (% chg)
$0.06 (+2.63%)
$0.06 (+2.63%)
Prev Close
$2.28
$2.28
Open
$2.28
$2.28
Day's High
$2.38
$2.38
Day's Low
$2.27
$2.27
Volume
76,056
76,056
Avg. Vol
298,436
298,436
52-wk High
$4.09
$4.09
52-wk Low
$1.59
$1.59
Revenue & Earnings Per Share
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
No consensus analysis data available.
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 35.24 | 32.21 | |
| P/E High - Last 5 Yrs. | -- | 41.33 | 45.93 | |
| P/E Low - Last 5 Yrs. | -- | 21.23 | 24.67 | |
| Beta | 0.28 | 0.75 | 0.79 | |
| Price to Sales (TTM) | 178.58 | 7.54 | 7.12 | |
| Price to Book (MRQ) | -- | 15.41 | 4.90 | |
| Price to Tangible Book (MRQ) | -- | 24.95 | 6.48 | |
| Price to Cash Flow (TTM) | -- | 24.44 | 24.70 | |
| % Owned Institutions | -- | 4.16 | 2.29 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.89 | 1.57 | |
| Dividend Yield - 5 Year Avg | -- | 1.13 | 0.77 | |
| Dividend 5 Year Growth Rate | -- | 17.49 | 4.07 | |
| Payout Ratio(TTM) | -- | 27.63 | 20.78 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -64.35 | 14.68 | 9.38 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -42.76 | 11.00 | 11.18 | |
| Sales - 5 Yr. Growth Rate | -5.00 | 8.90 | 8.21 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -54.02 | 79.36 | 24.18 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -28.03 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 19.77 | 10.39 | |
| Capital Spending - 5 Yr. Growth Rate | 36.90 | 9.71 | 10.42 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 0.14 | 2.44 | 2.53 |
| Current Ratio (MRQ) | 0.22 | 3.21 | 3.59 |
| LT Debt to Equity (MRQ) | -- | 28.67 | 11.47 |
| Total Debt to Equity (MRQ) | -- | 33.07 | 14.16 |
| Interest Coverage (TTM) | -149.72 | 16.59 | 30.45 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 17.36 | 58.01 | 54.23 | |
| Gross Margin - 5 Yr. Avg. | 50.95 | 57.58 | 52.19 | |
| EBITD Margin (TTM) | -153.74 | -- | -- | |
| EBITD - 5 Yr. Avg | -110.22 | 23.00 | 15.91 | |
| Operating Margin (TTM) | -244.46 | 19.12 | 3.78 | |
| Operating Margin - 5 Yr. Avg. | -131.86 | 15.69 | 11.22 | |
| Pre-Tax Margin (TTM) | -244.96 | 18.73 | 4.45 | |
| Pre-Tax Margin - 5 Yr. Avg. | -125.55 | 15.85 | 11.53 | |
| Net Profit Margin (TTM) | -244.96 | 14.51 | 1.07 | |
| Net Profit Margin - 5 Yr. Avg. | -125.55 | 10.97 | 7.86 | |
| Effective Tax Rate (TTM) | -- | 21.06 | 31.76 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 28.78 | 24.25 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 51,223 | 29,436,130 | 790,924,504 | |
| Net Income/Employee (TTM) | -125,474 | 3,734,402 | 92,823,068 | |
| Receivable Turnover (TTM) | 10.46 | 4.90 | 5.51 | |
| Inventory Turnover (TTM) | 3.58 | 3.01 | 3.47 | |
| Asset Turnover (TTM) | 0.80 | 0.76 | 0.88 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -195.99 | 10.70 | 10.41 | |
| Return on Assets - 5 Yr. Avg. | -60.29 | 8.94 | 11.41 | |
| Return on Investment (TTM) | -- | 14.18 | 13.05 | |
| Return on Investment - 5 Yr. Avg. | -76.85 | 11.67 | 14.78 | |
| Return on Equity (TTM) | -- | 16.92 | 14.90 | |
| Return on Equity - 5 Yr. Avg. | -79.39 | 14.14 | 16.12 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -42.76 | -18.76 | -5.00 |
| EPS (TTM) % | -28.09 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Antares Pharma Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA
- BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update
- BRIEF-Antares Pharma Q4 Loss Per Share $0.02
- BRIEF-Antares Pharma Provides Xyosted Regulatory Update
- BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted
Institutional Holders
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.